Please login to the form below

Not currently logged in
Email:
Password:

CSCC

This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends new Keytruda dosing schedule

CHMP recommends new Keytruda dosing schedule

Newcomer Libtayo from Sanofi and Regeneron recently received an FDA approval for use in metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery ... It made history by becoming the first

Latest news

  • Sanofi extends growth spurt thanks to Genzyme, Dupixent Sanofi extends growth spurt thanks to Genzyme, Dupixent

    CSCC) in the US last September. ... CSCC is a rare cancer with no other approved therapies, and that niche positioning helped sales reach $15m in the fourth-quarter, ahead of estimates and booked by Regeneron, Sanofi’s

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

  • As France protests, Sanofi takes axe to 670 jobs As France protests, Sanofi takes axe to 670 jobs

    dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics